Phase 1/2a, Multi-center, Open-Label, Dose-escalating Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenously Administered IPL344 for The Treatment of Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase I/II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs IPL-344 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Immunity Pharma
- 06 Sep 2019 Planned End Date changed from 15 Aug 2019 to 15 Aug 2020.
- 06 Sep 2019 Planned primary completion date changed from 15 Jul 2019 to 15 Jul 2020.
- 05 Sep 2018 New trial record